Arrowstreet Capital Limited Partnership Sells 564,314 Shares of Aurinia Pharmaceuticals Inc $AUPH

Arrowstreet Capital Limited Partnership decreased its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 34.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,076,118 shares of the biotechnology company’s stock after selling 564,314 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Aurinia Pharmaceuticals were worth $9,115,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Schroder Investment Management Group increased its position in Aurinia Pharmaceuticals by 74.0% during the 2nd quarter. Schroder Investment Management Group now owns 547,802 shares of the biotechnology company’s stock worth $4,640,000 after purchasing an additional 233,017 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Aurinia Pharmaceuticals by 45.7% during the second quarter. Virtus Investment Advisers LLC now owns 53,997 shares of the biotechnology company’s stock worth $457,000 after buying an additional 16,946 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter worth $204,000. State Board of Administration of Florida Retirement System lifted its stake in shares of Aurinia Pharmaceuticals by 240.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 143,885 shares of the biotechnology company’s stock valued at $1,219,000 after acquiring an additional 101,672 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 6.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 82,509 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 4,666 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AUPH has been the subject of a number of recent research reports. Leerink Partnrs cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $10.00 to $21.00 in a report on Friday, November 7th. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. Finally, Leerink Partners cut shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price target for the company from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Trading Down 1.0%

Shares of AUPH stock opened at $15.53 on Wednesday. Aurinia Pharmaceuticals Inc has a fifty-two week low of $6.55 and a fifty-two week high of $16.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.17 and a current ratio of 5.76. The stock has a 50 day simple moving average of $13.69 and a two-hundred day simple moving average of $11.36. The company has a market cap of $2.05 billion, a P/E ratio of 27.73 and a beta of 1.42.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.16 by $0.07. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.